findmyKOL

Fred Morady, MD

Enriched profile

McKay Professor of Cardiovascular Disease and Professor of Internal Medicine · University of Michigan Medical School

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Ann Arbor, MI · Midwest · United StatesSpecialtyClinical Cardiac ElectrophysiologyFocusAtrial Fibrillation
Active KOLfindmyKOL type: EliteLatest publication2015Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Fred Morady is McKay Professor of Cardiovascular Disease and Professor of Internal Medicine at University of Michigan Medical School. ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 13 Oct 2026

Fred Morady, MD, is McKay Professor of Cardiovascular Disease and Professor of Internal Medicine at University of Michigan Medical School, Ann Arbor, MI. The public record shows 661 publications with 37,364 citations (h-index 71), centered on Atrial Fibrillation. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 7 companies.

  • Top research focus: Atrial Fibrillation
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Atrial Fibrillation1 trial

Research focus

OpenAlex concept fingerprint
Atrial Fibrillation

Drugs & molecules

across trials, industry payments and publications
Evenitygeneric · RomosozumabClinical trials—Industry payments15Publications—Proliageneric · DenosumabClinical trials—Industry payments10Publications—Repathageneric · EvolocumabClinical trials—Industry payments9Publications—Otezlageneric · ApremilastClinical trials—Industry payments8Publications—Kerendiageneric · FinerenoneClinical trials—Industry payments3Publications—Austedogeneric · DeutetrabenazineClinical trials—Industry payments1Publications—Breztrigeneric · Budesonide / formoterol / glycopyrroniumClinical trials—Industry payments1Publications—Ibsrelageneric · TenapanorClinical trials—Industry payments1Publications—Jardiancegeneric · EmpagliflozinClinical trials—Industry payments1Publications—Tezspiregeneric · TezepelumabClinical trials—Industry payments1Publications—XIFAXANgeneric · RifaximinClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Amgen Inc.Clinical trials—Industry payments29Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments3AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2Ardelyx, Inc.Clinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Salix Pharmaceuticals, a division of Bausch Health US, LLCClinical trials—Industry payments1Teva Pharmaceuticals USA, Inc.Clinical trials—Industry payments1University of MichiganClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
71h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Oct 2026

7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    59.9%
    Antiarrhythmic27.2%
    Propafenone Hcl Er46%Propafenone Hcl23%Amiodarone Hcl23%Flecainide Acetate8%
    Part D<11 patients
    Beta blocker26.6%
    Metoprolol Succinate72%Metoprolol Tartrate19%Propranolol Hcl9%
    Part D<11 patients

    + 1 more class in this area

  • Blood & clotting

    40.1%
    Factor Xa inhibitor37.1%
    Eliquis76%Xarelto25%
    Part D≥40 patients
    Vitamin K antagonist3%
    Warfarin Sodium100%
    Part D<11 patients
Where care is delivered (Part B)85.4% facility · 14.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/fred-morady-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.